Norwood Appoints Vice President for Laser Project in North America.Business Editors & Health/Medical Writers MELBOURNE, Australia--(BUSINESS WIRE)--Sept. 27, 2002 Norwood Abbey Ltd. (ASX ASX See: Australian Stock Exchange :NAL NAL National Agricultural Library (Agricultural Research Service; US Department of Agriculture) NAL New American Library NAL National Accelerator Laboratory NAL National Aerospace Laboratory (Japan) ) today announced the appointment of Mark McLoughlin to head its laser project commercialization. Mark is a U.S. based career healthcare industry specialist. He will be responsible for coordinating all aspects of the laser project, including manufacturing, market development, sales, marketing and distribution. His initial task is to progress the market entry of the laser device and associated disposable tips in North America in conjunction with Ferndale Laboratories' proprietary topical anaesthetic an·aes·thet·ic adv. & n. Variant of anesthetic. anaesthetic or US anesthetic Noun a substance that causes anaesthesia Adjective causing anaesthesia Ela-Max(R). When used in conjunction with Norwood's laser, the waiting time for Ferndale's Ela-Max(R) is reduced from 30 minutes to just 5 minutes for procedures involving the use and insertion of needles. Regular joint management meetings between Norwood and Ferndale are preparing for the initial North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. product launch, while FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. marketing clearance review is currently in process. Additional product enhancements, flowing from in-field testing, are proceeding according to plan. The planning for the outsourcing of manufacturing and physical distribution is continuing. Mark McLoughlin will also be responsible for identifying and progressing the commercialization of other applications of the laser device. Areas that appear to offer the possibility of additional commercial arrangements include delivery of vaccines. The appointment of Mark McLoughlin represents the first step in Norwood's plans to attract experienced professionals to head up each of its projects. The fact that Mark is based in the U.S. should be seen as a further step in Norwood's recognition that a major part of its drug delivery device operations -- research & development partners, manufacturing partners, marketing partners and major product markets -- lies in North America. Mark McLoughlin joins Norwood after a distinguished career with American Hospital Supply Corporation, Baxter Healthcare Corporation, Mallinckrodt Inc. (a U.S. $2.6 billion global company with pharmaceutical, imaging and respiratory businesses) and Ion Beam Applications Inc. (a U.S. $250 million Belgium-based global technology company). ABOUT NORWOOD ABBEY Norwood Abbey Ltd. is a drug delivery and immunology company with three proprietary delivery platforms in various stages of commercialization and development. Its delivery technologies include laser-assisted delivery, micro-needle arrays and pressure wave technology for the transfer of both drugs and genetic material. In addition, the Company holds patent applications for the use of Gonadotropin gonadotropin /go·nado·tro·pin/ (-tro´pin) any hormone that stimulates the gonads, especially follicle-stimulating hormone and luteinizing hormone. Releasing Hormone (GnRH) analogue drugs in the regrowth Re`growth´ n. 1. The act of regrowing; a second or new growth. The regrowth of limbs which had been cut off. - A. B. Buckley. of the Thymus gland thymus gland (thī`məs), mass of glandular tissue located in the neck or chest of most vertebrate animals. In humans, the thymus is a soft, flattened, pinkish-gray organ located in the upper chest under the breastbone. and production of new T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. . GnRH drugs are already approved for the treatment of prostate and breast cancer and have been available on the market for many years. For further information about Norwood, visit the Company's web site at www.norwoodabbey.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion